In a randomized, open-label, phase II trial (MonarcHER; NCT02675231), the CDK4/6 inhibitor abemaciclib was assessed in patients with HR+/HER2+ advanced breast cancer (recurrent locally advanced, unresectable, or metastatic disease). Here, CDK4 is linked to breast carcinoma.